{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T23:37:34.863947+00:00","company":{"ticker":"MLAB","cik":724004,"company_name":"MESA LABORATORIES INC /CO/"},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"syndicate of banks led by JPMorgan Chase Bank, N.A.","detail":"credit_facility","count":1,"first_seen":"2024-04-08T23:59:59+00:00","last_seen":"2024-04-08T23:59:59+00:00","evidence_fact_ids":[62741]}]},"facts":[{"fact_type":"earnings_release","fact_key":"f7da1d93da19070d41e213c573b2f74a7f998a4c","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2026-05-27T12:00:13+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"three months ended March 31, 2026","report_date":"2026-05-27","result_type":"reported_results","revenue_text":null},"claim":"MESA LABORATORIES INC /CO/ reported financial results for three months ended March 31, 2026.","evidence_excerpt":"On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000724004-26-000039","anchor_url":"https://secwatch.observer/filing/0000724004-26-000039#claim-f7da1d93da19070d41e213c573b2f74a7f998a4c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/0000724004-26-000039-index.htm"},{"fact_type":"earnings_release","fact_key":"976ca7895fd5094d292bf5051bdfb420b7a3e1cb","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2026-05-27T12:00:13+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year ended March 31, 2026","report_date":"2026-05-27","result_type":"reported_results","revenue_text":null},"claim":"MESA LABORATORIES INC /CO/ reported financial results for fiscal year ended March 31, 2026.","evidence_excerpt":"On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000724004-26-000039","anchor_url":"https://secwatch.observer/filing/0000724004-26-000039#claim-976ca7895fd5094d292bf5051bdfb420b7a3e1cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/0000724004-26-000039-index.htm"},{"fact_type":"debt_financing","fact_key":"988c292a40b22dcb735e7084987c61f81c5dd78a","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2025-08-18T23:59:59+00:00","payload":{"counterparty":null,"effective_date":"2025-08-12","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"a base rate or a SOFR rate, plus an applicable spread","item_codes_triggered":["2.03"],"maturity_text":"April 5, 2029","principal_text":"$97 million"},"claim":"MESA LABORATORIES INC /CO/ incurred credit facility of $97 million at a base rate or a SOFR rate, plus an applicable spread maturing April 5, 2029.","evidence_excerpt":"On August 12, 2025, Mesa Laboratories, Inc. (\"the \"Company\") drew $97 million under its existing Credit Facility.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-027225","anchor_url":"https://secwatch.observer/filing/0001437749-25-027225#claim-988c292a40b22dcb735e7084987c61f81c5dd78a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774925027225/0001437749-25-027225-index.htm"},{"fact_type":"auditor_change","fact_key":"79e598ecb33e424856f11c13247b250414d57680","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Moss Adams LLP","disagreement_text":"During the year ended March 31, 2025, and the subsequent interim period through June 3, 2025, there were no (a) disagreements with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Moss Adams’ satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the Company’s financial statements, or (b) reportable events requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K.","effective_date":"2025-06-03","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Baker Tilly US, LLP"},"claim":"Moss Adams LLP resigned as auditor of MESA LABORATORIES INC /CO/.","evidence_excerpt":"On June 3, 2025, Mesa Laboratories, Inc., (the \"Company\") was notified that Moss Adams LLP (\"Moss Adams\"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001437749-25-019696","anchor_url":"https://secwatch.observer/filing/0001437749-25-019696#claim-79e598ecb33e424856f11c13247b250414d57680","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774925019696/0001437749-25-019696-index.htm"},{"fact_type":"material_agreement","fact_key":"bcf54f1ec15f3d4d8375b613c907770a35578f87","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-04-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Credit Agreement","agreement_type":"credit_facility","counterparty":"syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2024-04-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"MESA LABORATORIES INC /CO/ amended Credit Agreement with syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, Mesa Laboratories, Inc. (the “Company” “we” “us” or “our”) amended and restated its senior secured credit agreement (the “Credit Agreement”) with a syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-011307","anchor_url":"https://secwatch.observer/filing/0001437749-24-011307#claim-bcf54f1ec15f3d4d8375b613c907770a35578f87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774924011307/0001437749-24-011307-index.htm"},{"fact_type":"earnings_release","fact_key":"595d9e384c182601ab2c081f5b14c8d5d57a39f9","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-02-05T23:59:59+00:00","payload":{"eps_text":"$0.39 per diluted share of common stock","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2,116","period_text":"third fiscal quarter ended December 31, 2023","report_date":"2024-02-05","result_type":"reported_results","revenue_text":"$53,473"},"claim":"MESA LABORATORIES INC /CO/ reported third fiscal quarter ended December 31, 2023 results: revenue $53,473, net income $2,116, EPS $0.39 per diluted share of common stock.","evidence_excerpt":"● Non-GAAP adjusted operating income excluding unusual items as a percentage of revenues increased sequentially to 22.4% Executive Commentary (amounts in thousands) “Revenues of $53,473 for the quarter decreased 1.5% as compared to the third quarter of fiscal year 2023 (“3Q23”), due primarily to a 9.0% core organic revenues (“core organic”) decrease which was","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-003052","anchor_url":"https://secwatch.observer/filing/0001437749-24-003052#claim-595d9e384c182601ab2c081f5b14c8d5d57a39f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774924003052/0001437749-24-003052-index.htm"},{"fact_type":"executive_change","fact_key":"5e3138d34b","cik":724004,"ticker":"MLAB","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Capone was appointed as Director at MESA LABORATORIES INC /CO/.","evidence_excerpt":"Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-000821","anchor_url":"https://secwatch.observer/filing/0001437749-24-000821#claim-5e3138d34b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774924000821/0001437749-24-000821-index.htm"}]}